Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study☆

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial

“…[37] During the open-label stabilization phase, the most common reason for discontinuation was an AE, and the most common AEs leading to discontinuation (including somnolence, sedation, and fatigue) ( Table 4) were consistent with those observed during short-term monotherapy studies. [13][14][15] The most common AEs during the open-label phase (including somnolence, dry mouth, sedation, and fatigue) were more frequently reported during the first week of treatment.…”

“…[11,12] In patients with MDD, once daily extended release quetiapine fumarate (quetiapine XR) has demonstrated acute efficacy as monotherapy [13][14][15] and adjunct therapy. [16,17] The mode of action of quetiapine has not been fully understood.…”

Effects of Sustained Administration of Quetiapine Alone and in Combination with a Serotonin Reuptake Inhibitor on Norepinephrine and Serotonin Transmission

“…It was shown to be effective in the treatment of hQuet is a 3:1 mixture of Quet and NQuet. MDD when used alone, combined with antidepressants, or cognitive behavior therapy (McIntyre et al, 2007;El-Khalili et al, 2010;Bauer et al, 2009;Bortnick et al, 2011;Chaput et al, 2008;Cutler et al, 2009;Katila et al, 2008;Weisler et al, 2009). Not only the remission rate from MDD was increased, but the relapse was found to be less likely in patients who after alleviation of depressive symptoms were maintained on quetiapine (Liebowitz et al, 2010).…”

462 – Quetiapine monotherapy in acute phase for major depressive disorder: a metaanalysis of randomized, placebo-controlled trials

“…By reviewing the titles and abstracts, 136 trials were excluded since they clearly did not meet the criteria. Full papers of five studies were examined [30][31][32][33]39], two studies were excluded since one was a study of maintenance treatment [30] and the other studied in geriatric patients [39], only three trials [31][32][33], therefore, were included in the review. No relevant, unpublished study meeting the inclusion criteria was identified.…”

“…Recently, some randomized-controlled trials of quetiapine have been conducted in patients with MDD [30][31][32][33]. Since most of these studies have small samples, a meta-analysis, which is more powerful in estimating the true effect size, may be a strategy to confirm its efficacy and safety.…”